NOS3 and prostate cancer: Our previous study shows that eNOS exhibits a significant upregulation in clinical CRPC tissues and several in vitro and in vivo models of CRPC, and increased NO production can contribute to the antiandrogen resistance in prostate cancer cells via its suppression of AR activity [27].